Status: Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
Participants needed: 1,850
Trial details
Age: 18-130Biological sex: AllType: ObservationalSponsor: AstraZenecaUpdated: Jun 23, 2026Locations: 74
Eligibility criteria
Patient willing and able to provide written informed consent to participate in t... [+3]
Concurrent participation in any interventional trial for ATTR amyloidosis [+3]